Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129237) titled 'Efficacy and Response of Faricimab in Subretinal Hyperreflective Material in Neovascular Age-Related Macular Degeneration: A Prospective, Single-Center, Observational Study' on Aug. 1.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The Zhongshan Ophthalmic Center,Sun Yat-sen University
Condition:
Neovascular age-related macular degeneration
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-08-01
Target Sample Size: Faricimab treatment group for nAMD with SHRM:40;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/show...